prikaz prve stranice dokumenta Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
  Download
PDF 1.25 MB
Scientific paper - Review paper
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
Bone Marrow Transplantation, 57 (2022), 8; 1217-1239. https://doi.org/10.1038/s41409-022-01691-w
(European Society for Blood and Marrow Transplantation) Snowden, John A.; Sánchez-Ortega, Isabel; Corbacioglu, Selim; Basak, Grzegorz W.; Chabannon, Christian; de la Camara, Rafael; Dolstra, Harry; Duarte, Rafael F.; Glass, Bertram; Greco, Raffaella; Lankester, Arjan C.; Mohty, Mohamad; Neven, Bénédicte; de Latour, Régis Peffault; Pedrazzoli, Paolo; Perić, Zinaida; Yakoub-Agha, Ibrahim; Sureda, Anna; Kröger, Nicolaus More authors...

Cite this document

Snowden, J. A., Sánchez Ortega, I., Corbacioglu, S., Basak, G. W., Chabannon, C., de la Camara, R. ... Kröger, N. (2022). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplantation, 57. (8), 1217-1239. doi: 10.1038/s41409-022-01691-w

Snowden, John A., et al. "Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022." Bone Marrow Transplantation, vol. 57, no. 8, 2022, pp. 1217-1239. https://doi.org/10.1038/s41409-022-01691-w

Snowden, John A., Isabel Sánchez Ortega, Selim Corbacioglu, Grzegorz W. Basak, Christian Chabannon, Rafael de la Camara, Harry Dolstra, et al. "Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022." Bone Marrow Transplantation 57, no. 8 (2022): 1217-1239. https://doi.org/10.1038/s41409-022-01691-w

Snowden, J. A., et al. (2022) 'Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022', Bone Marrow Transplantation, 57(8), pp. 1217-1239. doi: 10.1038/s41409-022-01691-w

Snowden JA, Sánchez Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, and sur.. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplantation [Internet]. 2022 May 19 [cited 2024 October 05];57(8):1217-1239. doi: 10.1038/s41409-022-01691-w

J. A. Snowden, et al., "Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022", Bone Marrow Transplantation, vol. 57, no. 8, pp. 1217-1239, May 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:756558. [Accessed: 05 October 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
AuthorJohn A. Snowden
AuthorIsabel Sánchez-Ortega
AuthorSelim Corbacioglu
AuthorGrzegorz W. Basak
AuthorChristian Chabannon
AuthorRafael de la Camara
AuthorHarry Dolstra
AuthorRafael F. Duarte
AuthorBertram Glass
AuthorRaffaella Greco
AuthorArjan C. Lankester
AuthorMohamad Mohty
AuthorBénédicte Neven
AuthorRégis Peffault de Latour
AuthorPaolo Pedrazzoli
AuthorZinaida Perić
AuthorIbrahim Yakoub-Agha
AuthorAnna Sureda
AuthorNicolaus Kröger
CollaborationEuropean Society for Blood and Marrow Transplantation
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. This is the eighth special EBMT report on the indications for HCT for haematological diseases, solid tumours and immune disorders. Our aim is to provide general guidance on HCT indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered in conjunction with the risk of the disease, risk of HCT procedure and non-transplant strategies, including evolving cellular therapies. HCT techniques are constantly evolving and we make no specific recommendations, but encourage harmonisation of practice, where possible, to ensure experience across indications can be meaningfully aggregated via registry outputs. We also recommend working according to JACIE accreditation standards to maintain quality in clinical and laboratory components of practice, including benchmarking of survival outcomes. Since the last edition, the COVID-19 pandemic has affected clinical decision making and activity across indications. Although the full impact of the pandemic is yet to be determined, we recommend that decision making across indications is delivered with ongoing reference to EBMT and national COVID-19 guidance, in accordance with current local conditions.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBone Marrow Transplantation
Numberingvol. 57, no. 8, pp. 1217-1239
p-ISSN0268-3369
e-ISSN1476-5365
DOIhttps://doi.org/10.1038/s41409-022-01691-w
URN:NBNurn:nbn:hr:105:756558
Publication2022-05-19
Document URLhttps://www.nature.com/articles/s41409-022-01691-w
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-12-15 08:34:00